Poor
Needs Revision
Patient Risk:
Moderate
Summary
One extracted claim is not supported by the provided FDA label evidence (characterization as an “injectable long-acting antipsychotic” is absent), while schizophrenia indication is supported and bipolar I is only partially supported (maintenance monotherapy in adults).
Category Scores
Accurate Statements
Aripiprazole lauroxil is used for the treatment of schizophrenia.
Section 1 INDICATIONS AND USAGE: “for the treatment of schizophrenia in adults.”
Unsupported Statements
Aripiprazole lauroxil is an injectable long-acting antipsychotic.
Marked as absent from the label in the provided evaluation results.
Contradictions
Important Omissions
For bipolar I disorder, the label-supported context is “maintenance monotherapy treatment … in adults,” but the extracted claim does not specify maintenance monotherapy or adult-only indication.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
An indication-context mismatch (bipolar I described without maintenance/adult qualifiers) and an unsupported descriptive claim could mislead about appropriate labeling scope; no dosing/safety specifics were evaluated from the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
One extracted statement is not supported by the provided label evidence, and bipolar I indication is only partially supported due to missing maintenance/adult qualifiers.
Suggested Improvement
Remove or rephrase the unsupported “injectable long-acting antipsychotic” characterization unless supported by the provided label; for bipolar I, specify “maintenance monotherapy treatment of bipolar I disorder in adults” consistent with Section 1.